Occam Places Matthew Gall as CFO of iTeos Therapeutics
Occam has placed Matt Gall as CFO of iTeos, an MPM-backed immuno-oncology company that has raised over $200M in financing from marquee investors including RA Capital, Boxer, and Janus. Gall joins at an exciting phase in the company's development as multiple programs enter into the clinic.
Gall joins iTeos Therapeutics from Sarepta Therapeutics, Inc. where he was the Senior Vice President of Corporate Development and Treasurer. At Sarepta, Matthew led the Company’s recent multibillion partnership deal with Roche, and during his tenure, he oversaw the Company’s financial strategy and helped raise over $2 billion in capital. During his 15-year career in biotech, Matthew also worked at Celgene Corporation and Gilead Sciences in various roles including financial management and business development. Matthew holds an MBA from the University of Chicago Booth School of Business.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.